Workflow
Xilio Therapeutics(XLO) - 2024 Q4 - Annual Results
XLOXilio Therapeutics(XLO)2025-03-11 11:39

Financial Performance - The net loss for Q4 2024 was 13.1million,comparedto13.1 million, compared to 17.7 million in Q4 2023, and the full-year net loss was 58.2million,downfrom58.2 million, down from 76.4 million in 2023[15]. - Net loss for Q4 2024 was 13.093million,animprovementfromanetlossof13.093 million, an improvement from a net loss of 17.655 million in Q4 2023, representing a reduction of approximately 25.5%[23]. - Total assets increased to 71.075millioninDecember2024,upfrom71.075 million in December 2024, up from 60.926 million in December 2023, reflecting a growth of approximately 16.7%[21]. - Total liabilities rose to 53.477millioninDecember2024,comparedto53.477 million in December 2024, compared to 24.099 million in December 2023, indicating a substantial increase of 121.5%[21]. - The company reported total operating expenses of 15.353millionforQ42024,downfrom15.353 million for Q4 2024, down from 18.130 million in Q4 2023, a decrease of approximately 15.5%[23]. - Stock-based compensation expense for the year ended December 31, 2024, was 6.434million,downfrom6.434 million, down from 7.382 million in 2023, a decrease of about 12.8%[23]. - General and administrative expenses for the year ended December 31, 2024, totaled 24.778million,adecreasefrom24.778 million, a decrease from 26.997 million in 2023, reflecting a reduction of approximately 8.1%[23]. - Research and development expenses for the year ended December 31, 2024, were 41.211million,downfrom41.211 million, down from 52.136 million in 2023, a decrease of about 21.0%[23]. - General & Administrative (G&A) expenses were 6.5millionforQ42024,slightlyupfrom6.5 million for Q4 2024, slightly up from 6.4 million in Q4 2023, and totaled 24.8millionforthefullyear,downfrom24.8 million for the full year, down from 27.0 million in 2023[15]. Revenue and Payments - The company received 52.0millioninupfrontpaymentsfromAbbVieaspartofacollaborationagreement,withpotentialtotalcontingentpaymentsofapproximately52.0 million in upfront payments from AbbVie as part of a collaboration agreement, with potential total contingent payments of approximately 2.1 billion[10]. - License revenue for Q4 2024 was 1.7million,and1.7 million, and 6.3 million for the full year, compared to no license revenue in 2023[10]. - License revenue for Q4 2024 reached 1.724million,comparedto1.724 million, compared to 0 in Q4 2023, marking a significant increase[23]. - The company has deferred revenue of 32.780millionasofDecember31,2024,indicatinganewrevenuestream[21].CashPositionCashandcashequivalentswere32.780 million as of December 31, 2024, indicating a new revenue stream[21]. Cash Position - Cash and cash equivalents were 55.3 million as of December 31, 2024, an increase from $44.7 million as of December 31, 2023[10]. - Xilio expects its current cash position, along with the recent upfront payments, to fund operations into Q1 2026[11]. Clinical Development - Xilio reported a preliminary 27% objective response rate for vilastobart in patients without liver metastases during the Phase 2 trial, with a low incidence of immune-related adverse events, including only 5% reporting colitis[2][3]. - Xilio plans to submit an IND application for XTX501 in the middle of 2026, following promising preclinical studies[5][8]. - The company anticipates nominating a development candidate for its PSMA program in the ATACR format in Q3 2025 and submitting an IND application in Q1 2027[10]. Shareholder Information - The weighted average common shares outstanding increased to 64,675,807 in Q4 2024, compared to 27,557,021 in Q4 2023, indicating a significant increase of 134.5%[23].